Summary The European Childhood Leukaemia-Lymphoma Incidence Study (ECLIS) is designed to address concerns about a possible increase in the risk of cancer in Europe following the nuclear accident in Chernobyl in 1986. This paper reports results of surveillance of childhood leukaemia in cancer registry populations from 1980 up to the end of 1991. There was a slight increase in the incidence of childhood leukaemia in Europe during this period, but the overall geographical pattern of change bears no relation to estimated exposure to radiation resulting from the accident. We conclude that at this stage of follow-up any changes in incidence consequent upon the Chernobyl accident remain undetectable against the usual background rates. Our results are consistent with current estimates of the leukaemogenic risk of radiation exposure, which, outside the immediate vicinity of the accident, was small.
Summary Breast cancer is the second most common cancer among women in Madras and southern India after cervix cancer. The Madras Metropolitan Tumour Registry (MMTR), a population-based cancer registry, collects data on the outcome of cancer diagnosis by both active and passive methods. A total of 2080 cases of invasive female breast cancer were registered in MMTR during 1982-89. Of these, 98 (4.7%) cases were registered on the basis of death certificate information only (DCO), and there was no follow-up information for 235 (11.3%). These were excluded, leaving 1747 (84%) for survival analysis. The mean follow-up time was 43 months. The overall Kaplan-Meier observed survival rates at 1, 3 and 5 years were 80%, 58% and 48% respectively; the corresponding figures for relative survival were 81%, 61% and 51%. A multifactorial analysis of prognostic factors using a proportional hazards model showed statistically significant differences in survival for subjects in different categories of age at diagnosis, marital status, educational level and clinical extent of disease. Increasing age at diagnosis was associated with decreased survival. Single women displayed poorer survival (37.4%) at 5 years than those married and living with spouses (50.0%). The survival rate among those who had more than 12 years of education was higher (70%) at 5 years than that of illiterate subjects (47%). An inverse relationship was seen between survival rates and clinical extent of disease. The need for research to determine feasible public health approaches, allied to coordinated treatment facilities to control breast cancer in India, is emphasized.
Thailand is one of the few developing countries for which population-based cancer survival data are available. Using clinical follow-up information and reply-paid postal enquiries, 10,333 residents of Khon Kaen province registered with cancer in the period 1985-1992 were followed-up to the end of 1993. The sites of the most common cancers in the province were liver (5-year relative survival rate 9.2%), cervix (60.1%), lung (15.4%), breast (48.1%) and large bowel (41.9%). Results for Khon Kaen were compared with age-standardized survival data for the US and Scotland. Survival was consistently higher for US whites compared to Khon Kaen residents for those cancers whose prognosis is associated with early diagnosis (breast, cervix and large bowel) or the availability of intensive therapy (leukaemia and lymphoma). The main implication of these results for cancer control in Thailand is that the interventions of greatest potential benefit are those designed to promote early detection. More than one-third of all cancers in Thailand are liver tumours: primary prevention through control of hepatitis-B infection and liver fluke infestation is the only effective strategy for their control.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.